Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients

Journal of NeuroVirology

Volumn 22, Issue 1, 2016, Pages 88-92

  Calcagno, A ^a   Atzori, C ^b   Romito, A ^b   Vai, D ^b   Audagnotto, S ^a   Stella, M L ^a   Montrucchio, C ^a   Imperiale, D ^b   Di Perri, G ^a   Bonora, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIA VITTORIA HOSPITAL   (Italy)

Author keywords

Albumin ratio; Blood brain barrier; Neopterin; Phosphorylated tau; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEOPTERIN; SERUM ALBUMIN; TAU PROTEIN; ALBUMINOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER IMPAIRMENT; BRAIN DISEASE; CEREBROSPINAL FLUID; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE CELL LESION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SEIZURE; TREATMENT DURATION; VIRUS LOAD; HIV INFECTIONS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; VIROLOGY;

ADULT; ALBUMINS; AMYLOID BETA-PEPTIDES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BLOOD-BRAIN BARRIER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84957847453     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-015-0371-x     Document Type: Article

References (24)

1. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M (2002) Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 16:2145–2149
2. Abdulle S, Hagberg L, Gisslèn M (2005) Effects of antiretroviral treatment on blood–brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Medicine 6:164–169
3. Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O’Brien JT, Fox NC, Halliday GM, Schott JM (2014) Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry 85(12):1426–34
4. Ances BM, Hammoud DA (2014) Neuroimaging of HIV-associated neurocognitive disorders (HAND). Curr Opin HIV AIDS 9(6):545–51
5. Andersson LM, Hagbwerg L, Fuchs D, Svennerholm B, Gisslen M (2001) Increased blood brain-barrier permeability in neuroasymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 7:542–547
6. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–99
7. Babiloni C, Buffo P, Vecchio F, Onorati P, Muratori C, Ferracuti S, Roma P, Battuello M, Donato, Noce G, Di Campli F, Gianserra L, Teti E, Aceti A, Soricelli A, Viscione M, Andreoni M, Rossini PM, Pennica A (2014) Cortical sources of resting-state EEG rhythms in “experienced” HIV subjects under antiretroviral therapy. Clin Neurophysiol 125(9):1792–802
8. Borjabad A, Brooks AI, Volsky DJ (2010) Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol 5(1):44–62
9. Brown LA, Scarola J, Smith AJ, Sanberg PR, Tan J, Giunta B (2014) The role of tau protein in HIV-associated neurocognitive disorders. Mol Neurodegener 9:40
10. Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S (2014) Prevalence and predictors of blood–brain barrier damage in the HAART era. J Neurovirol 20(5):521–5
11. Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ (2015) APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals—a cross-sectional observational study. BMC Neurol 15:51
12. Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14):1747–51
13. Eugenin EA, Clements JE, Zink MC, Berman JW (2011) Human immunodeficiency virus infection of human astrocytes disrupts blood–brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 31(26):9456–65
14. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, Masliah E, Commins DL, Brandt D, Grant I, Singer EJ, Levine AJ, Miller J, Winkler JM, Fox HS, Luxon BA, Morgello S (2012) The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One 7(9):e46178
15. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, Price RW, Fuchs D (2010) Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 7:15. doi:10.1186/1742-6405-7-15
16. Hammond ER, Crum RM, Treisman GJ, Mehta SH, Marra CM, Clifford DB, Morgello S, Simpson DM, Gelman BB, Ellis RJ, Grant I, Letendre SL, McArthur JC, CHARTER Group (2014) The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol 180(3):297–307
17. Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, for the CHARTER Group (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60(3):473–80
18. McDonnell J, Haddow L, Daskalopoulou M, Lampe F, Speakman A, Gilson R, Phillips A, Sherr L, Wayal S, Harrison J, Antinori A, Maruff P, Schembri A, Johnson M, Collins S, Rodger A (2014) Cognitive impairment in people with HIV in the European region (CIPHER) study group. Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr 67(2):120–7
19. Mothapo KM, Stelma F, Janssen M, Kessels R, Miners S, Verbeek MM, Koopmans P, van der Ven A (2015) Amyloid beta-42 (Aβ-42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments. J Neuroimmunol 282:73–9
20. Peluso MJ, Spudich S (2014) Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics. Curr HIV/AIDS Rep 11(3):353–62
21. Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, Yiannoutsos CT, Spudich SS, Price RW (2014) Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One 9(12):e116081
22. Reiber H (1995) External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 41(2):256–63
23. Spudich S (2013) HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep 10(3):235–43
24. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, Spudich S, Gisslén M (2013) Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 10:62